Colorectal cancer chemoprevention: Is this the future of colorectal cancer prevention?

The Scientific World Journal

Volumn 2012, Issue , 2012, Pages

  Manzano, A ^a   Perez Segura P ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; LYSINE ACETYLSALICYLATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; SALICYLIC ACID DERIVATIVE; SULINDAC; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ABDOMINAL PAIN; ADENOMA; ADENOMATOUS POLYP; CANCER PREVENTION; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; COLORECTAL ADENOMA; COLORECTAL CANCER; DIARRHEA; DRUG DOSE COMPARISON; FOLLOW UP; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; NONHUMAN; REVIEW; ADULT; ANIMAL; COLON POLYPOSIS; COLORECTAL TUMOR; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADENOMA; ADENOMATOUS POLYPOSIS COLI; ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHEMOPREVENTION; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES; SULINDAC;

EID: 84861045864     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2012/327341     Document Type: Review

References (49)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. J., Cancer statistics, 2009 CA: A Cancer Journal for Clinicians 2009 59 4 225 249
2. Lynch H. T., de la Chapelle A., Hereditary colorectal cancer The New England Journal of Medicine 2003 348 10 919 932 (Pubitemid 36298000)
3. Hawk E. T., Levin B., Colorrectal cancer prevention Journal of Clinical Oncology 2005 23 378 391
4. Chan T. A., Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention The Lancet Oncology 2002 3 3 166 174
5. Arber N., Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point Cancer Epidemiology Biomarkers and Prevention 2008 17 8 1852 1857
6. Pisani P., Bray F., Parkin D. M., Estimates of the world-wide prevalence of cancer for 25 sites in the adult population International Journal of Cancer 2002 97 1 72 81
7. Kune G. A., Kune S., Watson L. F., Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study Cancer Research 1988 48 15 4399 4404
8. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group The New England Journal of Medicine 1989 312 3 129 135
9. Gann P. H., Manson J. E., Glynn R. J., Buring J. E., Hennekens C. H., Low-dose aspirin and incidence of colorectal tumors in a randomized trial Journal of the National Cancer Institute 1993 85 15 1220 1224 (Pubitemid 23223527)
10. Strmer T., Glynn R. J., Lee I. M., Manson J. A. E., Buring J. E., Hennekens C. H., Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study Annals of Internal Medicine 1998 128 9 713 720 (Pubitemid 28204862)
11. Cook N. R., Lee I. M., Gaziano J. M., Gordon D., Ridker P. M., Manson J. E., Hennekens C. H., Buring J. E., Low-dose aspirin in the primary prevention of cancer. The women's health study: a randomized controlled trial JAMA 2005 294 1 47 55 (Pubitemid 41002838)
12. Baron J. A., Cole B. F., Sandler R. S., Haile R. W., Ahnen D., Bresalier R., McKeown-Eyssen G., Summers R. W., Rothstein R., Burke C. A., Snover D. C., Church T. R., Allen J. I., Beach M., Beck G. J., Bond J. H., Byers T., Greenberg E. R., Mandel J. S., Marcon N., Mott L. A., Pearson L., Saibil F., Van Stolk R. U., A randomized trial of aspirin to prevent colorectal adenomas The New England Journal of Medicine 2003 348 10 891 899 (Pubitemid 36297997)
13. Benamouzig R., Deyra J., Martin A., Girard B., Jullian E., Piednoir B., Couturier D., Coste T., Little J., Chaussade S., Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial Gastroenterology 2003 125 2 328 336 (Pubitemid 36929412)
14. Sandler R. S., Halabi S., Baron J. A., Budinger S., Paskett E., Keresztes R., Petrelli N., Pipas J. M., Karp D. D., Loprinzi C. L., Steinbach G., Schilsky R., A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer The New England Journal of Medicine 2003 348 10 883 890 (Pubitemid 36297996)
15. Logan R. F. A., Grainge M. J., Shepherd V. C., Armitage N. C., Muir K. R., Aspirin and folic acid for the prevention of recurrent colorectal adenomas Gastroenterology 2008 134 1 29 38 (Pubitemid 350309319)
16. Cole B. F., Logan R. F., Halabi S., Benamouzig R., Sandler R. S., Grainge M. J., Chaussade S., Baron J. A., Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials Journal of the National Cancer Institute 2009 101 4 256 266
17. Dubé C., Rostom A., Lewin G., Tsertsvadze A., Barrowman N., Code C., Sampson M., Moher D., The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force Annals of Internal Medicine 2007 146 5 365 375 (Pubitemid 351650597)
18. Flossmann E., Rothwell P. M., Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies The Lancet 2007 369 9573 1603 1613 (Pubitemid 46710123)
19. Rothwell P. M., Wilson M., Elwin C. E., Norrving B., Algra A., Warlow C. P., Meade T. W., Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials The Lancet 2010 376 9754 1741 1750
20. Baron J. A., Sandler R. S., Bresalier R. S., Quan H., Riddell R., Lanas A., Bolognese J. A., Oxenius B., Horgan K., Loftus S., Morton D. G., A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas Gastroenterology 2006 131 6 1674 1682 (Pubitemid 44958508)
21. Bertagnolli M. M., Eagle C. J., Zauber A. G., Redston M., Solomon S. D., Kim K., Tang J., Rosenstein R. B., Wittes J., Corle D., Hess T. M., Woloj G. M., Boisserie F., Anderson W. F., Viner J. L., Bagheri D., Burn J., Chung D. C., Dewar T., Foley T. R., Hoffman N., Macrae F., Pruitt R. E., Saltzman J. R., Salzberg B., Sylwestrowicz T., Gordon G. B., Hawk E. T., Celecoxib for the prevention of sporadic colorectal adenomas The New England Journal of Medicine 2006 355 9 873 884 (Pubitemid 44315980)
22. Bertagnolli M. M., Eagle C. J., Zauber A. G., Redston M., Breazna A., Kim K., Tang J., Rosenstein R. B., Umar A., Bagheri D., Collins N. T., Burn J., Chung D. C., Dewar T., Foley T. R., Hoffman N., Macrae F., Pruitt R. E., Saltzman J. R., Salzberg B., Sylwestrowicz T., Hawk E. T., Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial Cancer Prevention Research 2009 2 4 310 321
23. Arber N., Eagle C. J., Spicak J., Rcz I., Dite P., Hajer J., Zavoral M., Lechuga M. J., Gerletti P., Tang J., Rosenstein R. B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A. G., Solomon S. D., Levin B., Celecoxib for the prevention of colorectal adenomatous polyps The New England Journal of Medicine 2006 355 9 885 895 (Pubitemid 44315981)
24. Bresalier R. S., Sandler R. S., Quan H., Bolognese J. A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M. A., Baron J. A., Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial The New England Journal of Medicine 2005 352 11 1092 1102 (Pubitemid 40365350)
25. Solomon S. D., McMurray J. J. V., Pfeffer M. A., Wittes J., Fowler R., Finn P., Anderson W. F., Zauber A., Hawk E., Bertagnolli M., Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention The New England Journal of Medicine 2005 352 11 1071 1080 (Pubitemid 40365348)
26. Rostom A., Dubé C., Lewin G., Tsertsvadze A., Barrowman N., Code C., Sampson M., Moher D., Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force Annals of Internal Medicine 2007 146 5 376 389 (Pubitemid 351650598)
27. Kearney P. M., Baigent C., Godwin J., Halls H., Emberson J. R., Patrono C., Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials British Medical Journal 2006 332 7553 1302 1305 (Pubitemid 44365384)
28. Meyskens F. L., McLaren C. E., Pelot D., Fujikawa-Brooks S., Carpenter P. M., Hawk E., Kelloff G., Lawson M. J., Kidao J., McCracken J., Albers C. G., Ahnen D. J., Turgeon D. K., Goldschmid S., Lance P., Hagedorn C. H., Gillen D. L., Gerner E. W., Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial Cancer Prevention Research 2008 1 1 32 38
29. Zell J. A., Pelot D., Chen W. P., McLaren C. E., Gerner E. W., Meyskens F. L., Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas Cancer Prevention Research 2009 2 3 209 212
30. Kinzler K. W., Nilbert M. C., Su L. K., Vogelstein B., Bryan T. M., Levy D. B., Smith K. J., Preisinger A. C., Hedge P., McKechnie D., Finniear R., Markham A., Groffen J., Boguski M. S., Altschul S. F., Horii A., Ando H., Miyoshi Y., Miki Y., Identification of FAP locus genes from chromosome 5q21 Science 1991 253 5020 661 665 (Pubitemid 21917199)
31. Bussey H. R. J., Familial Polyposis Coli: Family Studies, Histophatology, Diferential Diagnosis, and Results of Treatment 1975 Baltimore, Md, USA Johns Hopkins University Press
32. Waddell W. R., Loughry R. W., Sulindac for polyposis of the colon Journal of Surgical Oncology 1983 24 1 83 87 (Pubitemid 13004158)
33. Waddell W. R., Ganser G. F., Cerise E. J., Loughry R. W., Sulindac for polyposis of the colon American Journal of Surgery 1989 157 1 175 179 (Pubitemid 19041810)
34. Labayle D., Fischer D., Vielh P., Drouhin F., Pariente A., Bories C., Duhamel O., Trousset M., Attali P., Sulindac causes regression of rectal polyps in familial adenomatous polyposis Gastroenterology 1991 101 3 635 639
35. Giardiello F. M., Hamilton S. R., Krush A. J., Piantadosi S., Hylind L. M., Celano P., Booker S. V., Robinson C. R., Offerhaus G. J. A., Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis The New England Journal of Medicine 1993 328 18 1313 1316 (Pubitemid 23131373)
36. Giardiello F. M., Yang V. W., Hylind L. M., Krush A. J., Petersen G. M., Trimbath J. D., Piantadosi S., Garrett E., Geiman D. E., Hubbard W., Offerhaus G. J. A., Hamilton S. R., Primary chemoprevention of familial adenomatous polyposis with sulindac The New England Journal of Medicine 2002 346 14 1054 1059 (Pubitemid 34984619)
37. Wallace M. H., Lynch P. M., The current status of chemoprevention in FAP Familial Cancer 2006 5 3 289 294 (Pubitemid 44453860)
38. Steinbach G., Lynch P. M., Phillips R. K. S., Wallace M. H., Hawk E., Gordon G. B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L. K., Levin B., Godio L., Patterson S., Rodriguez-Bigas M. A., Jester S. L., King K. L., Schumacher M., Abbruzzese J., DuBois R. N., Hittelman W. N., Zimmerman S., Sherman J. W., Kelloff G., The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis The New England Journal of Medicine 2000 342 26 1946 1952 (Pubitemid 30419089)
39. Higuchi T., Iwama T., Yoshinaga K., Toyooka M., Taketo M. M., Sugihara K., A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients Clinical Cancer Research 2003 9 13 4756 4760 (Pubitemid 37323278)
40. Hallak A., Alon-Baron L., Shamir R., Moshkowitz M., Bulvik B., Brazowski E., Halpern Z., Arber N., Rofecoxib reduces polyp recurrence in familial polyposis Digestive Diseases and Sciences 2003 48 10 1998 2002 (Pubitemid 37410090)
41. Burn J., Bishop D. T., Chapman P. D., Elliott F., Bertario L., Dunlop M. G., Eccles D., Ellis A., Evans D. G., Fodde R., Maher E. R., Mslein G., Vasen H. F.A., Coaker J., Phillips R. K. S., Blow S., Mathers J. C., A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis Cancer Prevention Research 2011 4 5 655 665
42. Annie Y. H. J., Lin K. M., Ota D. M., Hereditary nonoplyposis colorrectal cancer: preventive management Cancer Treatment Reviews 2003 29 461 470 (Pubitemid 37428319)
43. Peltomki P., Vasen H., Mutations associated with HNPCC predispositionupdate of ICG-HNPCC/INSiGHT mutation database Disease Markers 2004 20 4-5 269 276 (Pubitemid 40164099)
44. 2010, http://www.oncoline.nl/
45. Jrvinen H. J., Aarnio M., Mustonen H., AktanCollan K., Aaltonen L. A., Peltomki P., Chapelle A. D. L., Mecklin J., Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer Gastroenterology 2000 118 5 829 834 (Pubitemid 30243745)
46. Ruschoff J., Wallinger S., Dietmaier W., Aspirin supresses the mutador phenotype associated with hereditary non-polyposis colorrectal cancer by genetic selection Proceedings of the National Academy of Sciences of the United States of America 1998 95 11301 11306 (Pubitemid 28450123)
47. Goel A., Chang D. K., Ricciardiello L., Gasche C., Boland C. R., A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells Clinical Cancer Research 2003 9 1 383 390 (Pubitemid 36109756)
48. Burn J., Bishop D. T., Mecklin J. P., Macrae F., Mslein G., Olschwang S., Bisgaard M. L., Ramesar R., Eccles D., Maher E. R., Bertario L., Jarvinen H. J., Lindblom A., Evans D. G., Lubinski J., Morrison P. J., Ho J. W. C., Vasen H. F. A., Side L., Thomas H. J. W., Scott R. J., Dunlop M., Barker G., Elliott F., Jass J. R., Fodde R., Lynch H. T., Mathers J. C., Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome The New England Journal of Medicine 2008 359 24 2567 2578
49. Lal G., Ash C., Hay K., Redston M., Kwong E., Hancock B., Mak T., Kargman S., Evans J. F., Gallinger S., Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor Cancer Research 2001 61 16 6131 6136 (Pubitemid 32762549)